Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.85
+$0.40 (+0.97%)
Nov 2, 2026, 9:56 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Net Income | -46.84M | -22.69M |
Depreciation & Amortization | n/a | 73K |
Stock-Based Compensation | 1.32M | 1.32M |
Other Working Capital | n/a | 427K |
Other Non-Cash Items | 1.35M | -663K |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | -52K | 375K |
Operating Cash Flow | -44.22M | -21.58M |
Capital Expenditures | n/a | -112K |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -148.21M | -15.74M |
Sales Maturities Of Investments | 25.06M | n/a |
Other Investing Acitivies | -135K | n/a |
Investing Cash Flow | -123.28M | -15.85M |
Debt Repayment | -46K | -46K |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | -414K | -414K |
Financial Cash Flow | 317.12M | -460K |
Net Cash Flow | 149.39M | -38.11M |
Free Cash Flow | -44.22M | -21.7M |
Adj. Free Cash Flow | -45.54M | -23.01M |
Maintenance CapEx | n/a | n/a |
Growth CapEx | n/a | n/a |
Owner Earnings | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove COAG